Peggy Scherle is the founder of Prelude Therapeutics. Prelude Therapeutics has raised $125M in total funding. Latest round: Growth.
Peggy Scherle, Ph.D., is the Chief Scientific Officer (CSO) at Prelude Therapeutics, a clinical-stage precision oncology company. She leads the discovery and development of small molecule therapies targeting cancer cell pathways. Scherle is based in Wilmington, Delaware, where the company is headquartered.
Full founder directory · Investor directory · Company funding database · Fundraising library